IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production
Bradda Head Lithium exceeds targets, secures US$3 million royalty and moves closer to productionView Video
IntelliAM aiming for significant growth with £5 million Aquis IPO
IntelliAM aiming for significant growth with £5 million Aquis IPOView Video

Latest Share Chat

India's Serum institute to sell AstraZeneca vaccine to private hospitals at $8/dose

Wed, 21st Apr 2021 08:15

NEW DELHI, April 21 (Reuters) - The Serum Institute of India
said on Wednesday it would sell the AstraZeneca vaccine
to the country's state governments at 400 rupees ($5.30) per
dose and to private hospitals at 600 rupees ($7.95).

"Furthermore, owing to the complexity, and urgency of the
situation it is challenging to supply it independently to each
corporate entity," it said in a statement. "We would urge all
corporate and private individuals to access the vaccines through
the state facilitated machinery and private health systems."
($1 = 75.4620 Indian rupees)
(Reporting by Krishna N. Das and Euan Rocha, editing by Louise
Heavens)

Related Shares

More News
3 Jul 2024 09:57

Aptamer shares jump as inks agreement with AstraZeneca

(Alliance News) - Aptamer Group PLC on Wednesday said it reached an agreement with AstraZeneca PLC.

2 Jul 2024 09:47

LONDON BROKER RATINGS: Deutsche Bank cuts Quilter, ups Polar Capital

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday:

1 Jul 2024 09:13

TOP NEWS: AstraZeneca cancer and Covid drugs recommended for approval

(Alliance News) - AstraZeneca PLC on Monday said two cancer treatments had been recommended for approval in the European Union, while there was also p...

1 Jul 2024 07:41

LONDON BRIEFING: Stocks called higher ahead of Thursday's election

(Alliance News) - Stocks in London are called to open higher on Monday, at the start of a politically fuelled week.

1 Jul 2024 07:17

AstraZeneca endometrial cancer treatment recommended for EU approval

(Sharecast News) - AstraZeneca announced on Monday that 'Imfinzi', or durvalumab, and 'Lynparza', or olaparib, have received a recommendation for appr...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.